327 related articles for article (PubMed ID: 16110345)
1. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline.
Youdim MB; Maruyama W; Naoi M
Drugs Today (Barc); 2005 Jun; 41(6):369-91. PubMed ID: 16110345
[TBL] [Abstract][Full Text] [Related]
2. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T
J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
Mandel S; Weinreb O; Amit T; Youdim MB
Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Youdim MB; Weinstock M
Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
[TBL] [Abstract][Full Text] [Related]
7. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
8. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.
Yogev-Falach M; Amit T; Bar-Am O; Youdim MB
FASEB J; 2003 Dec; 17(15):2325-7. PubMed ID: 14525944
[TBL] [Abstract][Full Text] [Related]
9. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Prog Neurobiol; 2010 Nov; 92(3):330-44. PubMed ID: 20600573
[TBL] [Abstract][Full Text] [Related]
10. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
11. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
Youdim MB; Gross A; Finberg JP
Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
[TBL] [Abstract][Full Text] [Related]
12. Type B and A monoamine oxidase and their inhibitors regulate the gene expression of Bcl-2 and neurotrophic factors in human glioblastoma U118MG cells: different signal pathways for neuroprotection by selegiline and rasagiline.
Inaba-Hasegawa K; Shamoto-Nagai M; Maruyama W; Naoi M
J Neural Transm (Vienna); 2017 Sep; 124(9):1055-1066. PubMed ID: 28577058
[TBL] [Abstract][Full Text] [Related]
13. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo.
Bar-Am O; Yogev-Falach M; Amit T; Sagi Y; Youdim MB
J Neurochem; 2004 Jun; 89(5):1119-25. PubMed ID: 15147504
[TBL] [Abstract][Full Text] [Related]
14. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
[TBL] [Abstract][Full Text] [Related]
15. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline.
Youdim MB; Weinstock M
Mech Ageing Dev; 2002 Apr; 123(8):1081-6. PubMed ID: 12044957
[TBL] [Abstract][Full Text] [Related]
16. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety.
Weinreb O; Amit T; Bar-Am O; Sagi Y; Mandel S; Youdim MB
J Neural Transm Suppl; 2006; (70):457-65. PubMed ID: 17017568
[TBL] [Abstract][Full Text] [Related]
17. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo.
Youdim MB; Wadia A; Tatton W; Weinstock M
Ann N Y Acad Sci; 2001 Jun; 939():450-8. PubMed ID: 11462801
[TBL] [Abstract][Full Text] [Related]
18. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.
Yogev-Falach M; Amit T; Bar-Am O; Weinstock M; Youdim MB
FASEB J; 2002 Oct; 16(12):1674-6. PubMed ID: 12206996
[TBL] [Abstract][Full Text] [Related]
19. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells.
Inaba-Hasegawa K; Akao Y; Maruyama W; Naoi M
J Neural Transm (Vienna); 2013 Mar; 120(3):435-44. PubMed ID: 22968599
[TBL] [Abstract][Full Text] [Related]
20. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.
Youdim MB; Amit T; Falach-Yogev M; Bar Am O; Maruyama W; Naoi M
Biochem Pharmacol; 2003 Oct; 66(8):1635-41. PubMed ID: 14555244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
